FILTER
FILTERED INTERVIEW RESULTS
Dr. Ross Sherlock
PROFESSOR, DIRECTOR OF MERC AND METAL EARTH, CHAIR IN EXPLORATION TARGETING, LAURENTIAN UNIVERSITY
The Mineral Exploration Research Centre (MERC) is a part of the Harquail School of Earth Sciences (HES) at Laurentian University in Sudbury, Ontario.
Carla Martínez
GENERAL MANAGER, CANADA PERU CHAMBER OF COMMERCE (CCCP)
A discussion about the challenges and opportunities for Canadian investors in Peru’s mining industry.
Jose Vizquerra
CEO & DIRECTOR, O3 MINING INC.
O3 holds a unique portfolio of assets in Quebec and Ontario and which it is exploring.
Michael Gribbons
CO-FOUNDER AND VICE PRESIDENT – SALES & MARKETING, MAESTRO DIGITAL MINE
Maestro Digital Mine discusses its latest innovations, and which factors are generating demand.
Víctor Gobitz
CEO, BUENAVENTURA
Buenaventura outlines progress at its diverse portfolio of Peruvian assets.
Terry Harbort
PRESIDENT & CEO, TALISKER RESOURCES
Talisker Resources outlines its developments at the Bralorne Gold Camp and the Spences Bridge Gold Belt in Southern BC.
Alistair Ross
PRESIDENT & CEO, ROCKCLIFF METALS CORP
Rockcliff outlines its objectives for its Canadian copper resources.
Ivan Rayo
GENERAL MANAGER, JRI
JRI is a Chilean engineering company that has been operating for 38 years and has been present in the construction and maintenance of the country’s most important mining projects, either as the main contracting company or a sub-contractor. The company has a market share of approximately 8% of the total engineering activity related to mining in the country.
Francisco Portilla
GENERAL MANAGER, PLASMA 4TH
Plasma 4th provides has developed cleaner, quieter and less invasive blasting solutions using plasma.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
